Polymerized type i collagen reduces chronic cyclosporine nephrotoxicity

Nephrology Dialysis Transplantation

Volumn 25, Issue 7, 2010, Pages 2150-2158

  Sánchez Pozos, Katy ^a,b   Lee Montiel, Felipe ^a,b   Pérez Villalva, Rosalba ^a,b   Uribe, Norma ^b   Gamba, Gerardo ^a,b,c   Bazan Perkins, Blanca ^d   Bobadilla, Norma A ^a,b  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^d INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

anti fibrotic drug; oxidative stress; tubular apoptosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CATALASE; COLLAGEN TYPE 1; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOSPORIN; GLUTATHIONE PEROXIDASE; KIDNEY INJURY MOLECULE 1; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; OXYGEN PEROXIDE; PEROXIDE; POLYMERIZED COLLAGEN TYPE 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ACTIN; CELL ADHESION MOLECULE; HAVCR1PROTEIN, RAT; IMMUNOSUPPRESSIVE AGENT; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERIOLOPATHY; ARTICLE; CHRONIC TOXICITY; CONTROLLED STUDY; ENZYME ACTIVITY; GLOMERULUS FILTRATION RATE; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; LIPID PEROXIDATION; MALE; MEAN ARTERIAL PRESSURE; MICROANGIOPATHY; MOUSE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; POLYMERIZATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; RENAL PROTECTION; SODIUM RESTRICTION; TUBULOINTERSTITIAL FIBROSIS; URINARY EXCRETION; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY; KIDNEY DISEASES; METABOLISM; PATHOPHYSIOLOGY; WISTAR RAT;

ACTINS; ANIMALS; CELL ADHESION MOLECULES; COLLAGEN TYPE I; CYCLOSPORINE; DISEASE MODELS, ANIMAL; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAPERITONEAL; KIDNEY; KIDNEY DISEASES; MALE; OXIDATIVE STRESS; POLYMERS; RATS; RATS, WISTAR; TRANSFORMING GROWTH FACTOR BETA;

EID: 77954344186     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq020     Document Type: Article

References (57)

1. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immu-nosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35: 333-346
2. Bjornholm M, Munzberg H, Leshan RL et al. Mice lacking inhibitory leptin receptor signals are lean with normal endocrine function. J Clin Invest 2007; 117: 1354-1360
3. Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333
4. Burdmann EA, Andoh TF, Yu L et al. Cyclosporine nephrotoxicity. Semin Nephrol 2003; 23: 465-476
5. Kopp JB, Klotman PE. Cellular and molecular mechanisms of cy-closporin nephrotoxicity. J Am Soc Nephrol 1990; 1: 162-179
6. Pichler RH, Franceschini N, Young BA et al. Pathogenesis of cyclo-sporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995; 6: 1186-1196
7. Shihab FS, Bennett WM, Tanner AM et al. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropa-thy. Kidney Int 1997; 52: 660-673
8. Zhong Z, Arteel GE, Connor HD et al. Cyclosporin A increases hyp-oxia and free radical production in rat kidneys: prevention by dietary glycine. Am J Physiol 1998; 275: F595-F604
9. Zhong Z, Connor HD, Yin M et al. Dietary glycine and renal dener-vation prevents cyclosporin A-induced hydroxyl radical production in rat kidney. Mol Pharmacol 1999; 56: 455-463
10. Feria I, Pichardo I, Juarez P et al. Therapeutic benefit of spironolac-tone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003; 63: 43-52
11. Vieira JM Jr, Noronha IL, Malheiros DM et al. Cyclosporine-induced interstitial fibrosis and arteriolar TGF-beta expression with preserved renal blood flow. Transplantation 1999; 68: 1746-1753
12. Ling H, Li X, Jha S et al. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol 2003; 14: 377-388
13. Bobadilla NA, Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol 2007; 293: F2-F9
14. Perez-Rojas JM, Bobadilla NA. Novel action of aldosterone in CsA nephrotoxicity. Rev Invest Clin 2005; 57: 147-155
15. Perez-Rojas J, Blanco JA, Cruz C et al. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2006; 292: F131-F139
16. Chimal-Monroy J, Bravo-Ruiz T, Furuzawa-Carballeda GJ et al. Collagen-PVP accelerates new bone formation of experimentally induced bone defects in rat skull and promotes the expression of osteo-pontin and SPARC during bone repair of rat femora fractures. Ann N Y Acad Sci 1998; 857: 232-236
17. Cervantes-Sanchez CR, Olaya E, Testas M et al. Collagen-PVP, a collagen synthesis modulator, decreases intraperitoneal adhesions. J Surg Res 2003; 110: 207-210
18. Olmos-Zuniga JR, Hernandez-Jimenez C, Diaz-Martinez E et al. Wound healing modulators in a tracheoplasty canine model. J Invest Surg 2007; 20: 333-338
19. Furuzawa-Carballeda J, Rojas E, Valverde M et al. Cellular and humoral responses to collagen-polyvinylpyrrolidone administered during short and long periods in humans. Can J Physiol Pharmacol 2003; 81: 1029-1035
20. Krotzsch-Gomez FE, Furuzawa-Carballeda J, Reyes-Marquez R et al. Cytokine expression is downregulated by collagen-polyvinylpyrroli-done in hypertrophic scars. J Invest Dermatol 1998; 111: 828-834
21. Furuzawa-Carballeda J, Alcocer-Varela J, Diaz dL. Collagen-PVP decreases collagen turnover in synovial tissue cultures from rheumatoid arthritis patients. Ann N Y Acad Sci 1999; 878: 598-602
22. Furuzawa-Carballeda J, Cabral AR, Zapata-Zuniga M et al. Subcutaneous administration of polymerized-type I collagen for the treatment of patients with rheumatoid arthritis. An open-label pilot trial. J Rheumatol 2003; 30: 256-259
23. Furuzawa-Carballeda J, Fenutria-Ausmequet R, Gil-Espinosa Vet al. Polymerized-type I collagen for the treatment of patients with rheumatoid arthritis. Effect of intramuscular administration in a double blind placebo-controlled clinical trial. Clin Exp Rheumatol 2006; 24: 514-520
24. Furuzawa-Carballeda J, Rodriquez-Calderon R, Diaz dL et al. Mediators of inflammation are down-regulated while apoptosis is up-regulated in rheumatoid arthritis synovial tissue by polymerized collagen. Clin Exp Immunol 2002; 130: 140-149
25. Furuzawa-Carballeda J, Krotzsch E, Barile-Fabris L et al. Subcutaneous administration of collagen-polyvinylpyrrolidone down regulates IL-1beta, TNF-alpha, TGF-beta1, ELAM-1 and VCAM-1 expression in scleroderma skin lesions. Clin Exp Dermatol 2005; 30: 83-86
26. Zeron HM, Krotzsch Gomez FE, Munoz RE. Pressure ulcers: a pilot study for treatment with collagen polyvinylpyrrolidone. Int J Derma-tol 2007; 46: 314-317
27. Perez-Rojas JM, Blanco JA, Gamba G et al. Low calorie commercial sugar is a sensitive marker of glomerular filtration rate. Kidney Int 2005; 68: 1888-1893
28. Ramirez V, Mejia-Vilet JM, Hernandez D et al. Radicicol, a heat shock protein 90 inhibitor, reduces glomerular filtration rate. Am J Physiol Renal Physiol 2008; 295: F1044-F1051
29. Davidson DW, Sackner MA. Simplification of the anthrone method for the determination of inulin in clearance studies. J Lab Clin Med 1963; 62: 351-356
30. Ramirez V, Trujillo J, Valdes R et al. Adrenalectomy prevents renal ischemia/reperfusion injury. Am J Physiol Renal Physiol 2009; 297: F932-F942
31. Lowry OH, Rosebrough NJ, Farr AL et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275
32. Aebi HE. Catalase. Methods of Enzymatic Analysis 1982; 273-286
33. Lawrence RA, Burk RF. Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun 1976; 71: 952-958
34. Thomas SE, Andoh TF, Pichler RH et al. Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. Kidney Int 1998; 53: 897-908
35. Amore A, Emancipator SN, Cirina P et al. Nitric oxide mediates cy-closporine-induced apoptosis in cultured renal cells. Kidney Int 2000; 57: 1549-1559
36. Healy E, Dempsey M, Lally C et al. Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line. Kidney Int 1998; 54: 1955-1966
37. Ortiz A, Lorz C, Catalan M et al. Cyclosporine A induces apoptosis in murine tubular epithelial cells: role of caspases. Kidney Int Suppl 1998; 68: S25-S29
38. Shihab FS, Andoh TF, Tanner AM et al. Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis. Kidney Int 1999; 56: 2147-2159
39. Shihab FS, Bennett WM, Yi H et al. Effect of pirfenidone on apopto-sis-regulatory genes in chronic cyclosporine nephrotoxicity. Transplantation 2005; 79: 419-426
40. Vaidya VS, Ramirez V, Ichimura T et al. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006; 290: F517-F529
41. Mizui M, Isaka Y, Takabatake Y et al. Electroporation-mediated HGF gene transfer ameliorated cyclosporine nephrotoxicity. Kidney Int 2004; 65: 2041-2053
42. NangakuM. Chronic hypoxia and tubulointerstitial injury: afinal common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17-25
43. Carvajal G, Rodriguez-Vita J, Rodrigues-Diez R et al. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdif-ferentiation. Kidney Int 2008; 74: 585-595
44. Patel S, Takagi KI, Suzuki J et al. RhoGTPase activation is a key step in renal epithelial mesenchymal transdifferentiation. J Am Soc Ne-phrol 2005; 16: 1977-1984
45. Zeisberg EM, Potenta SE, Sugimoto H et al. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008; 19: 2282-2287
46. Elberg G, Chen L, Elberg D et al. MKL1 mediates TGF-beta1-in-duced alpha-smooth muscle actin expression in human renal epithelial cells. Am J Physiol Renal Physiol 2008; 294: F1116-F1128
47. Wada T, Sakai N, Matsushima K et al. Fibrocytes: a new insight into kidney fibrosis. Kidney Int 2007; 72: 269-273
48. Ichimura T, Bonventre JV, Bailly V et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998; 273: 4135-4142
49. Han WK, Alinani A, Wu CL et al. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol 2005; 16: 1126-1134
50. Vaidya VS, Ford GM, Waikar SS et al. A rapid urine test for early detection of kidney injury. Kidney Int 2009; 76: 108-114
51. Ichimura T, Asseldonk EJ, Humphreys BD et al. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phago-cytic phenotype on epithelial cells. J Clin Invest 2008; 118: 1657-1668
52. Kaushal GP, Basnakian AG, Shah SV. Apoptotic pathways in ische-mic acute renal failure. Kidney Int 2004; 66: 500-506
53. Daemen MA, van't Veer C, Denecker G et al. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest 1999; 104: 541-549
54. Moreno G, Merino A, Mercado A et al. Electroneutral Na-coupled cotransporter expression in the kidney during variations of NaCl and water metabolism. Hypertension 1998; 31: 1002-1006
55. Wang C, Salahudeen AK. Lipid peroxidation accompanies cyclo-sporine nephrotoxicity: effects of vitamin E. Kidney Int 1995; 47: 927-934
56. Durak I, Karabacak HI, Buyukkocak S et al. Impaired antioxidant defense system in the kidney tissues from rabbits treated with cyclospor-ine. Protective effects of vitaminsEandC. Nephron 1998; 78: 207-211
57. Tariq M, Morais C, Sobki S et al. N-acetylcysteine attenuates cyclos-porin-induced nephrotoxicity in rats. Nephrol Dial Transplant 1999; 14: 923-929